Donoghue Forlines LLC Biogen Inc. Transaction History

Donoghue Forlines LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $646,804 - $814,939	-3,338 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$223.92 - $287.77 $241,385 - $310,216	1,078 Added 47.7%	3,338 $801,000
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $639,557 - $834,053	2,260 New	2,260 $640,000
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $965,240 - $1.13 Million	-3,973 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$236.26 - $355.63 $938,660 - $1.41 Million	3,973 New	3,973 $973,000
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $2.15 Million - $2.41 Million	-6,984 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $1.96 Million - $2.3 Million	6,984	6,984 $2.19 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Donoghue Forlines LLC, based on Form 13F filings with the SEC.

Stay updated on Donoghue Forlines LLC with notifications on news.